Commercialisation of Cellular Immunotherapies for Cancer

Anthony Walker and Rob Johnson, Managing Partners at Alacrita, have published a paper on Commercialization of Cell Therapies

Biochemical Society Transactions,  2016,44(2)329-332;
doi: 10.1042/bst20150240

 

Successful commercialisation of a cell therapy requires more than proving safety and efficacy to the regulators. The inherent complexity of cellular products delivers particular manufacturing, logistical and reimbursement hurdles that threaten commercial viability for any therapy with a less than spectacular clinical profile that truly changes the standard of care. This is particularly acute for autologous cell therapies where patients receive bespoke treatments manufactured from a sample of their own cells and where economies of scale, which play an important role in containing the production costs for small molecule and antibody therapeutics, are highly limited. Nevertheless, the promise of ‘game-changing’ efficacy, as exemplified by very high levels of complete responses in refractory haematological malignancies, has attracted capital investments on a vast scale, and the attendant pace of technology development provides promising indicators for future clinical and commercial success.

 

See full text here

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Stay in touch